ESR1 ligand binding domain mutations in hormone-resistant breast cancer

Seventy percent of breast cancers express estrogen receptor (ER) and most of these are sensitive to ER inhibition. However, many such tumors become refractory to inhibition of estrogen action in the metastatic setting for unknown reasons. We conducted a comprehensive genetic analysis of two independ...

Descripción completa

Detalles Bibliográficos
Autores principales: Toy, Weiyi, Shen, Yang, Won, Helen, Green, Bradley, Sakr, Rita A., Will, Marie, Li, Zhiqiang, Gala, Kinisha, Fanning, Sean, King, Tari A., Hudis, Clifford, Chen, David, Taran, Tetiana, Hortobagyi, Gabriel, Greene, Geoffrey, Berger, Michael, Baselga, Jose, Chandarlapaty, Sarat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903423/
https://www.ncbi.nlm.nih.gov/pubmed/24185512
http://dx.doi.org/10.1038/ng.2822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903423/
https://www.ncbi.nlm.nih.gov/pubmed/24185512
http://dx.doi.org/10.1038/ng.2822

Ejemplares similares